Nonsteroidal antagonists of the mineralocorticoid receptor

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 5, 2015, Pages 417-424

  Kolkhof, Peter ^a   Nowack, Christina ^a   Eitner, Frank ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Aldosterone; Hyperkalemia; Mode of action

Indexed keywords

CS 3150; DSR 71167; EPLERENONE; FINERENONE; LY 2623091; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MT 3995; NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONIST; PF 03882845; SM 368229; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIABETIC NEPHROPATHY; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE EXPRESSION; HEART DISEASE; HEART FAILURE; HUMAN; HYPERKALEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; TISSUE DISTRIBUTION; ANIMAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM;

EID: 84942608331     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000147     Document Type: Review

References (52)

1. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015; 65:257-263. This article focuses on the current knowledge and understanding of the direct roles of aldosterone and mineralocorticoid receptor activation in heart and kidneys, including common pathophysiological mechanisms in both organs and implications for the clinical use of MRAs in the trea tment of cardiac and renal diseases.
2. Lother A, Moser M, Bode C, et al. Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol 2015; 55:8.1-8.24.
3. DuPont JJ, Hill MA, Bender SB, et al. Aldosterone and vascular mineralocorticoid receptors: regulators of ion channels beyond the kidney. Hypertension 2014; 63:632-637.
4. Schwenk MH, Hirsch JS, Bomback AS. Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis 2015; 22:123-132. These authors have provided a comprehensive overview of mineralocorticoid receptor-blocking therapy in prote inuric CKD. Available MRAs directly target the inflammatory and fibrotic effects of aldosterone in CKD patients, but their use is limited because of unresolved safety issues. 5.
5. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy: beyond the RAS Nat. Rev Nephrol 2014; 10:325-346. This is an excellent review on current clinical approaches in diabetic nephropathy. The authors emphasize that ins u fficient understanding of drug mechanisms and the pathogenesis of diabetic kidney disease, heterogeneity of trial populations and a paucity of hard outcomes are major causes of recent failures in clinical trials.
6. Zannad F, Gat tis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33:2782-2795.
7. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure J Card Fail 2004; 10:297-303.
8. Dinsdale C, Wani M, Steward J, O'Mahony MS. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing 2005; 34:395-398.
9. Piotrowski DW. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. J Med Chem 2012; 55:7957-7966.
10. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012; 350:310-317.
11. Tamargo J, Solini A, Ruilope LM. Comparison of agents that affect aldosterone action. Semin Nephrol 2014; 34:285-306.
12. Luther JM. Is there a new dawn for selective mineralocorticoid receptor antagonism? Curr Opin Nephrol Hypertens 2014; 23:456-461.
13. Collin M, Niemann F, Jaisser F. Mineralocorticoid receptor modulators: a patent review (2007-2012). Expert Opin Ther Pat 2014; 24:177-183. In this review article, the authors give a comprehensive overview of patents on MRA modulators which were published between the years 2007 and 2012. The authors conclude that novel nonsteroidal MRAs with particular pharmacokinetic profiles may avoid the undesirable renal side-e ffects of steroidal MRAs. These so-called ' kidney friendly MRAs' are expected to become a clear breakthrough in the field.
14. Pitt B,Filippatos G,Gheorghiade M,et al. Rationale and design of ARTS: a rand omized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease Eur J Heart Fail 2012 14 668-6675.
15. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel nonsteroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34:2453-2463.
16. Ruilope LM, Agarwal R, Chan JC, et al. Rationale design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol 2014; 40:572-581.
17. Bakris GL, Nowack C, Ruilope LM. Results of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes and diabetic nephropathy. In: World Congress of Nephrology 2015, 13-17 March 2015, Cape Town, South Africa http://www.abstracts2view.com/wcn/view.php?nu=WCN15L-SUN-488&terms=. [Accessed 2 0 May 2015] ARTS-DN was a double-blind, placebo-controlled, parallel-group, multicenter study in patients with diabetic nephropathy (T2DM and albuminuria30 mg/g) receiving an ACE inhibitor or angiotensin receptor blocker and a serum potassium of at least 4.8 mmol/l at screening. Once-daily oral finerenone reduced albuminuria dose-dependently. Statistically significant differences in albuminuria reduction compared with placebo were observed with the four highest doses (7.5-20 mg once daily). The inci d ence of an eGFR decrease of at least 30% was not different between the placebo group and the finerenone groups. Hyperkalemia leading to discontinuation was not observed in the placebo and finerenone 10mg groups; incidences in the finerenone 7.5, 15 and 20mg groups were as low as 2.1, 3.2 and 1.7%, respectively.
18. Pitt B, Anker SD, Böhm M, et al. Filippatos G rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure ( ARTS-HF): a randomized study of finerenone versus eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Failure 2015; 17:224-232.
19. Fraczkiewi cz R, Lobell M, Göller AH, et al. Best of both worlds: combining pharma data and state of the art modeling technology to improve in silico pKa prediction. J Chem Inf Model 2015; 55:389-397.
20. Ertl P , Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000; 43:3714-3717.
21. Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012; 7:1385-13403.
22. Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid recepto r (MR) antagonist for hypertension and nephropathy. J Med Chem 2010; 53:5979-6002.
23. Yang C, Shen HC, WuZ, et al. Discovery of novel oxazolidinedione derivatives as potent and selective mineraloco rticoid receptor antagonists. Bioorg Med Chem Lett 2013; 23:4388-4392.
24. Cox JM, Chu HD, Yang C, et al. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series. Bioorg Med Chem Lett 2014; 24:1681-1684.
25. Nariai T, Fujita K, Mori M, et al. SM-368229, a novel selective and potent nonsteroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. J Pharmacol Sci 2011; 115:346-353.
26. Nariai T, Fujita K, Mori M, et al. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology 2012; 89:44-52.
27. Nariai T, Fujita K, Mori M, et al. SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. J Cardiovasc Pharmacol 2012; 59:458-464.
28. Nariai T, Fujita K, Kawane K, et al. DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, s eparates urinary sodium excretion and serum potassium elevation in rats. J Pharmacol Exp Ther 2015; 354:2-9; doi: 10.1124/jpet.114.221341. [Epub ahead of print].
29. Hasui T, Matsunaga N, Ora T, et al. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. J Med Chem 2011; 54:8616-8631.
30. Hasui T, Ohra T, Ohyabu N, et al. Design, synthesis, and structure-Activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists. Bioorg Med Chem 2013; 21:5983-5994.
31. Hasui T, Ohyabu N, Ohra T, et al. Discovery of 6-[5-(4-fluorophenyl)-3-methylpyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists. Bi oorg Med Chem 2014; 22: 5428-5445.
32. US National Library of Medicine. ClinicalTrials.gov [online] http://www.clinicaltrials. gov/ct2/show/NCT01889277 (2014). [Accessed 20 May 2015]
33. US N ational Library of Medicine. ClinicalTrials.gov [online] http://www.clinicaltrials. gov/ct2/show/NCT02345057 (2015). [Accessed 20 May 2015]
34. US National Library of Medicine. ClinicalTrials.gov [online] http://www.clinicaltrials. gov/ct2/show/NCT02345044 (2015). [Accessed 20 May 2015]
35. Orena S, Maurer TS, She L, et al. PF-03882845, a nonsteroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol 2 013; 4:115. doi: 10.3389/fphar.2013.00115.
36. Casimiro-Garcia A, Piotrowski DW, Ambler C, et al. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-meth oxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. J Med Chem 2014; 57:4273-4288.
37. Futatsugi K,Piotrowski DW,Casimiro-Garcia A,et al. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists. Bioorg Med Chem Lett 2013 23 6239-6242.
38. Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014; 64:69-78. In this study, the autho rs carefully determined minimal effective doses of finerenone and eplerenone with respect to acute renal electrolyte effects (natriuresis) and to chronic end-organ protective effects. They found that finerenone reduced cardiac hypertrophy and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses.
39. Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects Eur Heart J 2013; 34:2426-2428.
40. Rogerson FM, Yao YZ, Young MJ, Fuller PJ. Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator. FASEB J 2014; 28:4200-4210
41. Yang J, Fuller PJ, Morgan J, et al. Use of phage display to identify novel mineralocorticoid receptor-interacting proteins. Mol Endocrinol 2014; 28:1571-1584. These au thors identified eukaryotic elongation factor 1A1 (EEF1A1), structurespecific recognition protein 1 (SSRP1) and X-ray repair cross-complementing protein 6 (XRCC6) as novel interacting partners of the mineralocorticoid receptor. Interestingly, these cofact o rs demonstrated ligand-, promoter-And cell-specific modulation of mineralocorticoid receptor-mediated transactivation which would also support the concept of developing compounds which may possess tissuespecific MRA activity.
42. Yan g J, Fuller PJ, Morgan J, et al. GEMIN4 functions as a coregulator of the mineralocorticoid receptor. J Mol Endocrinol 2015; 54:149-160.
43. Shibata S, Rinehart J, Zhang J, et al. Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab 2013; 18:660-671.
44. Gomez-Sanchez EP, Gomez-Sanchez CE. Central regulation of blood pressure by the mineralocorticoid receptor. Mol Cell Endocrinol 2012; 350:289-298.
45. Bolton EE, Chen J, Kim S, et al. PubChem3D: a new resource for scientists. J Cheminform 2011; 3:32.
46. Inspra Drug Approval Package, 2003. Pharmacological Review Inspra Drug Approval Package 21-437/S-002, FDA US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/n da/2003/21-437S002-Inspra-Pharmr.pdf. [Accessed 20 May 2015]
47. Nordeen SK, Bona BJ, Beck CA, et al. The two faces of a steroid antagonist: when an antagonist isn't. Steroids 1995; 60:97-104.
48. Massaad C, Lombé s M, Aggerbeck M, et al. Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone. Mol Pharmacol 1997; 51:285-292.
49. Fagart J, H illisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010; 285:29932-29940.
50. Hultman ML, Krasnoperova NV , Li S, et al. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 2005; 19:1460-1473.
51. Grune J, Benz V, Brix S, et al. Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist in a model of pressure overload-induced cardiac hypertrophy. In: Conference American Heart Association's High Blood Pre ssure Research 2014 Scientific Sessions, HBPR 2014, San Francisco, CA, Hypertension 64 (-):ABSTR 007 (2014).
52. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295:2465-2468.